#Cleantech and #ClimateChange #Podcast – dynaCERT Inc. (TSX: $DYA.TO) (OTCQX: $DYFSF) Management Discusses their ‘Global Solution to Reduce Pollution’ @dynaCERT

 #Cleantech and #ClimateChange #Podcast – dynaCERT Inc. (TSX: $DYA.TO) (OTCQX: $DYFSF) Management Discusses their ‘Global Solution to Reduce Pollution’ @dynaCERT

 

Management Recaps Milestones Achieved in 2020 and Future Goals for their #Hydrogen #Technology 

 

Point Roberts WA, Delta BC, December 31, 2020  – Investorideas.com, a global news source and leading investor resource covering cleantech and renewable energy stocks (Renewableenergystocks.com) issues a special edition of the Cleantech and Climate Change Podcast, talking about today's problems and solutions for the future.

 

Investorideas.com talks to Jim Payne, President & CEO and Jean-Pierre Colin, Executive Vice President & Director of cleantech company dynaCERT Inc. (TSX: DYA.TO) (OTCQX: DYFSF) (FRA: DMJ). They discuss the milestones achieved in 2020 that set the stage for success in 2021 and beyond for their “Global Solution to Reduce Pollution.”

 

Listen to the Podcast:

https://www.investorideas.com/Audio/Podcasts/2020/123020-dynaCERT.mp3

 

Read this in full at https://www.investorideas.com/news/2020/cleantech-climatechange/12311dynaCERT-Global-Solution-Reduce-Pollution.asp

 

Listen to the cleantech and climate change podcast on Spotify

 

Jean-Pierre Colin, Executive Vice President & Director talked to Investor Ideas about the accomplishments and milestones achieved by dynaCERT Inc. in 2020 saying, “We spent 16 years and over $60 million to develop the hydrogen technology with a line of products that reduces pollution and reduces fuel costs in all diesel engines. Globally, there's an estimated one billion diesel engines around the world and transportation, logistics generators, construction equipment, mining, marine locomotives. So we have a huge market and 2020 was the combination of those 16 years that came before.”

 

Continued: “We're proud to say that we've achieved many milestones in 2020. First of all, financial growth; the best in the company's history. At the close of the year, we're closing 2020 with $20 million in cash, a very strong balance sheet. In 2019, we had $4 million in assets and in 2020 we have over $20 million in assets.”

Continued: “We listed on the Toronto Stock Exchange in July to better access sources of capital and offer more rigorous corporate governance to our shareholders in Canada. We also listed on the OTCQX best market in the United States in June 2020.”

 

Continued: “We also brokered a three times oversubscribed institutional underwritten financing in July 2020 which assured independent due diligence by Canada's top securities dealers. And as importantly, in that financing we added 20 new institutional shareholders. They became shareholders of dynaCERT for the first time.”

 

Continued: “In 2020 we created a wholly owned subsidiary of dynaCERT called dynaCERT International Strategic Holdings, or DISH to facilitate sales and expand the financing options for our clients, the early adopters of our hydrogen technology. One of our dealers in Canada and the US has already started drawing down on that program and we now offer it to our 45 other dealers around the world as a monthly subscription program.”

 

Continued: “Also in 2020 we took advantage of the widely applied imposed Pandemic Covid-19 shutdown. During the shutdown we added and expanded. We added professionals and we added and expanded our research and development department. But as importantly, we set up a semi- automated assembly line with an estimated annual capacity of 72,000 units. That would mean a capacity for sales of almost $445 million per year and operating income of over $200 million per year.”

 

Discussing their corporate decision to stay the course with their global mission to provide a global solution to reduce pollution he said, “I think great decisions come from knowledge, intelligence and dedication, and decisions come from the leaders who have access to all the information of the battlefield. Those who are aligned with our goals and all of our sincere shareholders want us to stay the course.”

 

Jim Payne, President and CEO discussed how the company integrated longevity into the corporate strategy noting. ”This is a global solution to reduce pollution that works now. This is technology that we're not thinking we can do, or hoping we can do; it's done. It's proven worldwide. Along with that, you look at all the patents that we've got. Just last week I was talking to an analyst and he was saying, “You know Jim, that one worldwide pattern you've got on the means and methods of monitoring and monetizing carbon credits with an internal combustion engine, that’s a trillion dollars in itself.”

 

Continued:  “We also firmly believe that with the 16 years of experience and the engineering, research and development. it puts in the perfect vision to take advantage of the hydrogen economy.  I have believed for a long time that the hydrogen economy was huge and it appears that the world is just now waking up to that reality again. The technology we have today is  a bridge to that hydrogen economy that we're going to continue to expand and grow because it has now gained worldwide recognition within the hydrogen field.”

 

In closing he said, “My mission has always been to create a win-win situation. First of all, I'm a grandfather of nine grandchildren, so I am so thrilled to be able to be part of something that I believe is going to make such a significant difference to leave this world in a better place.”

 

dynaCERT Inc. manufactures and distributes Carbon Emission Reduction Technology for use with internal combustion engines. As part of the growing global hydrogen economy, our patented technology creates hydrogen and oxygen on-demand through a unique electrolysis system and supplies these gases through the air intake to enhance combustion, resulting in lower carbon emissions and greater fuel efficiency. Our technology is designed for use with many types and sizes of diesel engines used in on-road vehicles, reefer trailers, off-road construction, power generation, mining and forestry equipment, marine vessels and railroad locomotives. Website: www.dynaCERT.com.

 

Thanks, that’s it for today. Do something good for this beautiful planet each and every day.

 

Podcast host: Dawn Van Zant, founder of Investorideas.com

If you would like to be a guest on this podcast and tell your story please call me at 800 665 0411

For investors following cleantech stocks we do have a directory of publicly traded stocks – visit

https://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp

 

The Investorideas.com podcasts are also available on iTunes, Spotify, Tunein, Sticher, Spreaker.com, iHeart.com and Google Play Music.

 

Visit the Cleantech and Climate Change Podcast page at Investorideas.com

 

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

The Investorideas.com podcasts are also available on iTunes, Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio and Google Play Music.

 

Visit the Podcast page at Investorideas.com:

https://www.investorideas.com/Audio/

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: Disclosure: dynaCERT is a paid monthly news and publishing client on Investorideas.com. More disclaimer and disclosure info https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android  

Join our Investor Club https://www.investorideas.com/membership/

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

Contact Investorideas.com

800 665 0411

 

 

Investor Ideas #Potcasts 511, #Cannabis News and #Stocks on the Move; #Psychedelic Spotlight (OTCQB: $ALID) (CSE: $PULL.C) (CSE: $NOVA.C)

 

Investor Ideas #Potcasts 511, #Cannabis News and #Stocks on the Move; #Psychedelic Spotlight (OTCQB: $ALID) (CSE: $PULL.C) (CSE: $NOVA.C)

 

Delta, Kelowna, BC, December 30, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca  release today’s podcast edition of  cannabis news and stocks to watch plus insight from thought leaders and experts.

 

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2020/123020-StocksToWatch.mp3

 

Read this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/12301ALID-PULL-NOVA.asp

 

Hear the investor ideas potcast on Spotify

 

Hear Investor ideas cannabis potcast on iTunes  

 

Today’s podcast overview/transcript:

 

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

 

In today’s podcast we will be looking at a few private and public company announcements, specifically focussing on the psychedelic sector.

 

SYNTAC Institute, an Alberta-based non-profit organization dedicated to bringing legal psychedelic-assisted therapy to Canadians, recently confirmed that it has facilitated the first announced approval from Health Canada for an Alberta-based patient facing a terminal illness diagnosis.

 

The legal exemption from the Canadian Drugs and Substances Act, granted by the Office of Controlled Substances at Health Canada, paves the way for Calgary resident Anthony White to immediately undergo psilocybin-assisted treatment to deal with the severe mental health challenges that come with a terminal medical diagnosis.  White's situation has been even more difficult to contend with as he is in his forties and has a young daughter.

 

Under the Section 56 Exemption approved by Health Canada, White will now be eligible to participate in a therapy process overseen by a medical team that includes the use of psilocybin, an active hallucinogenic substance found in "magic mushrooms".

 

"Facing this devastating prognosis has been incredibly difficult, but I am grateful I can soon gain some comfort and relief through this promising therapy.  I appreciate the help from the folks at SYNTAC to bring this to reality, and to Health Canada for putting the patient first in this important decision."

 

Encouraging research continues to emerge that suggests psychedelic-assisted therapeutic approaches to mental and emotional health conditions demonstrate remarkable efficacy and outcomes for a variety of conditions including end-of-life distress, Post Traumatic Stress Disorder (PTSD), depression and anxiety.

 

"We are extremely grateful to Health Canada and the Hon. Minister Hajdu and her team for delivering this exemption so that Mr. White can immediately access this innovative therapy," stated David Harder, Executive Director of SYNTAC Institute in Calgary.

 

"We are also deeply appreciative of the tireless efforts of Dr. Bruce Tobin and his team at Therapsil in Victoria B.C. for putting in so much of the groundwork required for this kind of announcement to be possible."

 

With the traditional approach to mental health and wellness in Canada already struggling, COVID-19 is creating a tsunami of mental and emotional health challenges that threaten to overwhelm the Canadian healthcare system.  "We believe psychedelic medicines will be a huge part of the solution that Canadians need and deserve", added Harder.

 

"We are not only incredibly thrilled for Mr. White gaining immediate access to this powerful therapeutic tool, but also for every Canadian who is suffering with mental and emotional health challenges.  This is another step forward in the battle against our country's mental health crisis."

 

 

Allied Corp (OTCQB: ALID) – an international medical cannabis company focused on creating and providing health solutions to address today’s medical mental health issues, recently announced the signing of a letter of intent to acquire the psilocybin company Pacific Sun Fungi. This further expands upon Allied’s press release of October 20, 2020 communicating the submission of the provisional patent for Allied’s functional mushroom formulation targeting major depression and anxiety.

Pacific Sun is a British Columbia corporation that has been working on Research and Development activities in the psilocybin space for the past 10 years. Pacific Sun holds several formulations that have been tested under physician supervision. Pacific Sun also has proprietary extraction technology, proprietary formulations for several specific disease targets and physician-led therapy protocols that have proven to be effective for several specific disease targets.

Over the past two years, in parallel with psilocybin moving into the pharmaceutical research realm, Allied has continued to develop its pharmaceutical research infrastructure. This represents the evolution of Allied beyond specific cannabis-based therapies to more pharma-based health targets.

Allied was born out of the need to support veterans and first responders suffering from PTSD with targeted cannabinoid solutions. This acquisition has advanced Allied into the broader mental health market encompassing both pharmaceutical and natural health products. Building upon our experience with PTSD, we are expanding our research and treatment options to encompass depression, anxiety and general mental health. This puts Allied in the unique position to provide a full-scope, closed-loop therapy protocol. Typical psilocybin therapies support the patient for an episodic micro-dosing treatment regime which follows a specific dosing and wash out cycle. Unfortunately, this leaves the patient with a treatment gap between dosing periods. This can now be bridged with Allied’s existing cannabinoid treatment solutions. A “full scope treatment” option.

The proprietary “Allied full scope treatment” offers the patient continual therapy with treatment options both before and after the psilocybin treatment period. This is accomplished by offering Allied’s cannabinoid and natural health products combined with the psilocybin products and protocols. This will all be accomplished under legal license and physician supervision.

A timeline leading towards Allied as being positioned as a leader in this space:

●      In 2018, the FDA recognized psilocybin therapies as a “breakthrough” therapy for PTSD and Major Depressive Disorder. (Food and Drug Administration, 2018).

●      In 2019, Imperial College of London and John Hopkins open the first psychedelic research centers. MAPS clinics across the nation conduct research on psilocybin therapy. (Forbes.com, 2019).

●      In 2020, Health Canada approves psilocybin for select patient with terminal illness. 2020 Oregon State decriminalizes psilocybin. On November 30, 2020 Oregon state issues call for participants in State Guidance Committee. Allied executive applies to be a member of this committee. (Health Canada, 2020 and Oregon State Health, 2020).

●      On October 20, 2020, Allied submits provisional patent on drug formulation containing psilocybin and a combination of additional functional mushrooms for the disease targets of PTSD, depression and general anxiety. (Allied Corp press release of Oct 20, 2020).

●      On December 20^th, 2020, Allied moves to acquire Pacific Sun Fungi by signing Letter of Intent to acquire.

Allied’s initial focus will be on pharmaceutical R&D while also entering the Oregon State market with additional markets to follow as legislation allows. As well, Allied is in the process of applying for a Section 56 exemption in Canada for Allied’s Physician group to be able to prescribe Allied’s formulation to veterans and first responders. With this infrastructure in place, Allied will be able to be one of the first companies to come to market in the psilocybin space with both psilocybin products augmented by Allied’s current natural health and cannabis-derived pharma products.

 

Pure Extracts Technologies Corp. (CSE: PULL) announced that it is commencing a study on the formulation and manufacturing of psilocybin based active treatments for oral tablets, capsules and a nasal gel that will be used as an investigational product. The study with be conducted at the Toronto Institute of Pharmaceutical Technology (“TIPT”) by Dr. Alexander MacGregor, a key scientific advisor to the Company.

 

The study will focus on formulating, manufacturing and clinical bioavailability testing of rapid onset psilocybin dosage forms that could be used in future efficacy clinical trials by both Pure Extracts and its pharmaceutical customers. Clinical batch manufacturing, packaging and labelling are all included in the study as is conformity testing and stability testing (including both long-term and accelerated). The study will conform to both Canadian Good Manufacturing Practice (“GMP”) and Good Clinical Practice (“GCP”) standards.

 

Dr. MacGregor is a pharmaceutical science inventor, an expert in pharmaceutical technology and novel drug delivery systems. He is a recipient of several global patents in the field of medical treatments and pharmaceutical drug delivery technologies most notably from Canada, US, Australia, Europe, Latin America, China, India and Japan. Dr. MacGregor’s inventions have led to groundbreaking therapeutic drugs for the treatment of cancer, management of diabetes, systemic infections and post-operative pain. His company has a Health Canada Drug Establishment License, a Cannabis Drug License and a Dealer’s License issued under the Controlled Drugs and Substances Act (CDSA) and is thus licensed to possess psychedelic drug compounds.

 

Pure Extracts CEO, Ben Nikolaevsky, remarked, “Having the support of TIPT, one of Canada’s premiere pharmaceutical R&D companies, while waiting to receive our Dealer’s License from Health Canada is invaluable. We are very excited to be laying the groundwork for our move into the controlled substances world of psychedelics and to be furthering our knowledge-base in psilocybin and associated novel delivery mechanisms.”

 

Nova Mentis Life Science Corp. (CSE: NOVA) (OTC: LIBFF)

announced that it has added two additional psychedelic compounds to its drug portfolio. NOVA has contracted with its U.S. partner to begin manufacturing the active pharmaceutical ingredients (API), baeocystin and aeruginascin. NOVA is currently developing C-GMP API psilocybin at its U.S. partner's facility which has highly trained quality control staff on site and certifies all release testing prior to human studies. Per contractual agreements, NOVA has ownership of the API Drug Master Files ("DMF's"), which will be used for regulatory submission prior to commencing human clinical trials.

 

"The availability of greater than 95 per cent pure synthetic psilocybin, baeocystin and aeruginascin will allow the creation of unique combinatory formulations with potential therapeutic applications to various subsets of ASD," stated Marvin S. Hausman MD, Chairman of NOVA's Scientific Advisory Board. "Furthermore, the availability of these compounds will allow our collaborative scientific chemists to develop technology to deliver our proprietary formulations to organ systems outside of the brain. Are there tryptamine related therapeutic receptors in the small intestine, colon and liver that need to be discovered?"

 

Baeocystin is an analog of psilocybin and is found in most psilocybin mushrooms along with other minor tryptamine derivatives. Aeruginascin is also a tryptamine derivative and an analog of psilocybin, but it occurs naturally within a different mushroom, Inocybe aeruginascens. The pharmacological effects of both of these compounds are not well understood and anecdotal usage reports reveal different euphoric experiences.

It is theorized that psilocybin and mushroom tryptamine derivatives, such as baeocystin and aeruginascin, when utilized in concert, may produce what is referred to as an "entourage effect". This theory was proposed for cannabis compounds but essentially is applicable to other compounds within natural foods that work together to create unique effects and benefits.

 

Pending final production of the additional API compounds, NOVA plans to test their efficacy and potential "entourage effect" related therapeutic benefits in the autism spectrum disorder (ASD) preclinical rat model that was designed by Dr. Viviana Trezza at Roma Tre University, Rome, Italy.

 

 

 

 

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.

 

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

 

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

Investorideas.com podcasts are also available on iTunes,  Spotify, Google Play Music, Stitcher, Spreaker,   YouTube via Spreaker,  iHeartradio and Tunein.

 

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

 

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:

https://www.investorideas.com/About/Private_Policy.asp

 

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

 

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800 665 0411

 

 

 

 Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory

 

The #AIEye #Podcast 502: GBT Tokenize (OTCPINK: $GTCH) Developing qNET Security Protocol for qTerm Vital Signs Device, and Datametrex (TSXV: $DM.V) Announces German Versions of NexaSecurity and NexaSMART; #Artificialintelligence

 

 

The #AIEye #Podcast 502: GBT Tokenize (OTCPINK: $GTCH) Developing qNET Security Protocol for qTerm Vital Signs Device, and Datametrex (TSXV: $DM.V) Announces German Versions of NexaSecurity and NexaSMART; #Artificialintelligence

 

Global Smart Machines Market to Grow $10.79 Billion from 2020-2024

 

Point Roberts WA, Vancouver BC – December 30, 2020  – Investorideas.com (www.investorideas.com), a global investor news source covering Artificial Intelligence (AI) brings you today’s edition of  The AI Eye-  watching stock news, deal tracker and advancements in artificial intelligence  –  featuring technology company GBT Technologies Inc. (OTCPINK:GTCH).

 

Listen to today’s podcast:

https://www.investorideas.com/Audio/Podcasts/2020/123020-AI-Eye.mp3

 

Read this in full at https://www.investorideas.com/news/2020/artificial-intelligence/12301GTCH-DM.asp

 

Hear the Ai Eye on Spotify  

 

Today’s Column- The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence

 

Stocks discussed: (OTCPINK:GTCH) (TSXV:DM)

 

GBT Tokenize Corp, the joint venture of GBT Technologies Inc. (OTC PINK:GTCH), is developing a new security protocol, code name qNET, for its qTerm human vital signs device. According to the press release, qNET will include “methods for node's identification, packet exchange and formatting rules,” and “will have a security policy that is supervised by GBT's AI system.” Danny Rittman, GBT’s CTO, explained:

 

“qTerm vital device will be using private and confidential users information and it is our highest priority to protect it. That is why we are investing in the development of qNET, a dedicated, private network security protocol, especially designed for qTerm. qNET will include a high and low level security protocol since it is planned to be used for communication over the internet. Within qNET we are adopting government security standards, guidelines and high levels of encryption technology. We are going to use our database sharing segmentation methods according to the recent patent that was granted by the USPTO earlier this month.”

 

Datametrex AI Limited (TSXV:DM) has announced the release of German language capabilities for its AI-based NexaSecurity and NexaSMART- Social Media Automated Reporting Technology. Datametrex CEO, Marshall Gunter, said:

 

"This latest development opens up almost all of Europe and the German-speaking market, which is the world's fourth largest economy by GDP and has a huge need for artificial intelligence-based tools to counter social media-based disinformation campaigns.

 

As mentioned in our investor webinar, market expansion plans for international markets are being realized by investing income from our COVID19-test-kit sales into the development of our core technology, artificial intelligence-based analytics."

 

 

Global Smart Machines Market to Grow $10.79 Billion from 2020-2024

 

A report published by Technavio finds that the global Smart Machines market will grow by $10.79 billion from 2020 to 2024 with a compound annual growth rate (CAGR) of 12 percent. An excerpt from the report snapshot reads:

 

The smart machines market by expert systems has been gaining traction owing to the increase in investments in automating processes that were performed mainly by human labor. The forecast period will see a growth in the market coming from sectors such as healthcare, defense retail, agriculture, finance, and commerce. These machines will be increasingly adopted to replace human experts in areas such as diagnosis, prediction, design, planning, monitoring, debugging, and repair.

 

Sam Mowers, Investorideas.com

 

Read and hear other editions of the AI  Eye

 

For a list of artificial intelligence stocks on Investorideas.com visit here

Investors can trade these stocks and other ideas on our site using our  list of top stock trading apps including Robinhood , Acorn, Stash  and others.

About GBT Technologies Inc.

GBT Technologies Inc. (OTC PINK: GTCH) (“GBT”) (http://gbtti.com) is a development-stage company which considers itself a native IoT creator, developing Internet of Things (IoT) and Artificial Intelligence (AI) enabled mobile technology platforms.  GBT has a portfolio of Intellectual Property that, when commercialized, will include smart microchips, mobile and security applications and protocols, and supporting cloud software.  GBT’s system envisions the creation of a global mesh network.  The core of the system will be its advanced microchip technology that can be installed in any mobile or fixed device worldwide. GBT envisions this system as a low-cost, secure, private mesh network between any enabled devices, providing shared processing, advanced mobile database management/sharing and enhanced mobile features as an alternative to traditional carrier services.

 

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

The Investorideas.com podcasts are also available on iTunes,  Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio and Google Play Music.

 

Visit the Podcast page at Investorideas.com:

https://www.investorideas.com/Audio/

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com  Disclosure : GTCH is a paid monthly AI client on Investorideas

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

The AI Eye-  Watching stock news, deal tracker and  advancements in artificial intelligence is an original content brand of Investorideas.com

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800 665 0411

 

Get more Technology stock investor ideas - news, articles, podcasts and stock directories